Biogen Inc. (BIIB) Q1 2019 Earnings Results

Biogen Beats on EPS, Stock Down 2.52%

Biogen's earnings report showed a positive surprise on EPS, but the stock fell by 2.52% following the announcement. Investors may be concerned about the lack of revenue details and forward guidance, which could indicate uncertainty about future performance. The cautious tone from management might also have contributed to the stock's decline.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$6.98	N/A	+0.56%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautious optimism about future prospects. They emphasized their commitment to innovation despite a competitive market.

Management highlighted the ongoing commitment to innovation in neurology.

They acknowledged the competitive landscape but expressed confidence in their pipeline.

There was a focus on maintaining operational efficiency.

Biogen Beats on EPS, Stock Down 2.52%

Key numbers

Management commentary

Biogen Inc.

More earnings this week

Biogen Beats on EPS, Stock Down 2.52%

Key numbers

Management commentary